News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look, Wallstreet is selling !!!
04/17/2023 12:49:30 EDT 14.336214
04/17/2023 12:49:12 EDT 14.38100
04/17/2023 12:49:02 EDTI 14.3320
04/17/2023 12:48:53 EDTI 14.381
04/17/2023 12:48:42 EDTI 14.4123
04/17/2023 12:47:14 EDTI 14.3320
04/17/2023 12:47:06 EDTI 14.3810
04/17/2023 12:47:06 EDTI 14.391
04/17/2023 12:47:06 EDTI 14.3810
04/17/2023 12:47:06 EDTI 14.3810
04/17/2023 12:47:06 EDTI 14.38
It's unbelievable, we are in the middle of a real earthquake.
If, yes, if all the control organizations would work. This neoliberal agenda of deregulation could be the beginning of the end with our example.
Sorrento with JJ are laying the groundwork to stop these brute capitalist machinations of Wall Street.
What we need is media publicity to expose everything. It would be so, so important and good for this financial center.
I believe it's a 52% stake as well..
Maybe this will make you rethink the future of SRNEQ and SCILEX....
https://www.reddit.com/r/BANDOFBROTHERSOFSRNE/comments/12c87pk/are_the_pieces_falling_into_place_for_an_epic/?utm_source=share&utm_medium=android_app&utm_name=androidcss&utm_term=1&utm_content=share_button
|
Followers
|
280
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
14953
|
|
Created
|
03/09/07
|
Type
|
Free
|
| Moderators | |||
While being laser-focused on just one objective can have its advantages, having a wider-based remit can be just as effective, if done well.
That is certainly the opinion of Alliance Global analyst James Molloy when evaluating Sorrento’s prospects.
So, what’s on offer from the Sorrento menu in the near-term?
The company has already filed an EUA for COVI-STIX, a 15-minute nasal swab antigen test for SARS-CoV-2, in the US and Mexico, and the test could be launched as early as 1H21.
Accurate COVID tests are still needed in the US and around the globe, and Molloy expects the assay to gain EUA approval and could “rapidly approach $500M in sales as soon as 2022.“
SRNE's 8-minute SARS-CoV-2 antibody test COVID-TRACK could swiftly follow in its footsteps with an EUA anticipated to be filed in the year’s first half, too. “This could easily be another $500million+ near term opportunity,” Molloy said.
Furthermore, the company’s two neutralizing antibody treatments, COVI-DROPS and COVI-AMG, against SARS-CoV-2, could be launched in 2022. Each of these, as well, have the potential to bring in more than $500 million in sales, according to the analyst
The company’s non-opioid pain pipeline also has several late-stage catalysts.
Fast tracked by the FDA, Phase 3 data for sciatica pain candidate SP-102 should be available this year, while RTX for OsteoArthritis (OA) knee pain and intractable cancer pain will kick-off Phase 2 and Phase 3 studies, respectively, in 2021. Both target “substantial market opportunities.”
Last but not least is Abivertinib, the company's oncology lead candidate, indicated for non-small-cell lung cancer (NSCLC) and B-cell lymphomas, and currently in Phase 3 trials in China with top line data anticipated in 1H21.
To this end, based on the progress of the company's pipeline, Molloy sees significant gains in SRNE's future. The analyst rates the stock a Buy and his $35 price target implies a hefty 277% upside. (To watch Molloy’s track record, click here)
Overall, Sorrento currently has few, yet very positive analysts tracking its progress. With Buy ratings only – 3, in total - the stock has a Strong Buy consensus rating. There’s plenty of upside projected, too; At $28.67, the average price target suggests gains of ~209% over the next 12 months. (See SRNE stock analysis on TipRanks)
4955 Directors Place
San Diego, CA 92121
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-GUARD™, COVI-AMG™, COVI-SHIELD™, Gene-MAb™, COVI-MSC™ and COVI-DROPS™; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit?www.sorrentotherapeutics.com
AI
